USPTO serial 79302096
PREVENTIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 29, 2022
- Examiner
- BULLOFF, TOBY ELLEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PREVENTIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | diagnostic and analytical means for medical purposes in particular chemical preparations for use in disease prevention, namely, for detecting and preventing infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemical preparations for use in medical and pharmaceutical detection kits, namely, for detecting infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemicals for medical diagnostics and analysis relating to infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces; gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; all the aforesaid goods not for veterinary use; chemicals for medical diagnostics and analysis in the nature of chemical preparations for rapid testing of infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 21, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 30, 2023 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Sep 11, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 19, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 19, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 29, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 29, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 11, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 11, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 10, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 22, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 22, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 22, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 9, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 9, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 9, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 9, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 9, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 22, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 22, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 22, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 13, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 21, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 21, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 20, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 19, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 21, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 19, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jan 7, 2021 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |